Viewing Study NCT00947167


Ignite Creation Date: 2025-12-25 @ 12:31 AM
Ignite Modification Date: 2025-12-25 @ 10:37 PM
Study NCT ID: NCT00947167
Status: TERMINATED
Last Update Posted: 2017-03-03
First Post: 2009-07-23
Is NOT Gene Therapy: False
Has Adverse Events: True

Brief Title: A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Sponsor: Pamela L. Kunz
Organization: